Related Experiment Video
Updated: Jan 26, 2026
10:55
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
2.7K
Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Maryam Zanjirband1, Soheila Rahgozar1
1Department of Cellular and Molecular Biology, Faculty of Science, University of Isfahan, Azadi Square, Isfahan, Iran.
Current Drug Targets
|April 6, 2019
Summary
MDM2-p53 antagonists are novel cancer therapeutics targeting the p53 pathway. This review covers their development, clinical trials, and future challenges in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The p53 tumor suppressor is frequently inactivated in human cancers.
- MDM2 protein inhibits p53, maintaining low p53 levels in normal cells.
- Targeting the MDM2-p53 interaction is a promising cancer therapy strategy.
Purpose of the Study:
- To review advances in MDM2-p53 antagonists for cancer therapy.
- To discuss the mechanism of action, clinical trials, and resistance mechanisms.
- To highlight future directions in this therapeutic area.
Main Methods:
- Review of scientific literature on MDM2-p53 inhibitors.
- Analysis of clinical trial data for MDM2 antagonists.
- Discussion of predictive biomarkers and combination strategies.
Main Results:
- Small molecule inhibitors targeting the MDM2-p53 binding pocket are in clinical trials.
- Understanding p53-dependent and -independent effects is crucial.
- Gene signatures may predict sensitivity to MDM2 antagonists.
Conclusions:
- MDM2-p53 antagonists represent a significant advancement in targeted cancer therapy.
- Further research is needed to overcome resistance and optimize treatment strategies.
- Addressing challenges like hematotoxicity is essential for clinical success.
Related Concept Videos
01:23Negative Regulator Molecules
38.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.3K
01:52Eukaryotic Transcription Inhibitors
10.9K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K
01:25Strategies for Assessing and Addressing Confounding
374
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
374
02:38Molecules and Compounds
68.4K
Atoms and Molecules
68.4K
01:45Positive Regulator Molecules
134.9K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
134.9K
01:23Dipeptidyl Peptidase 4 Inhibitors
626
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
626